Influvac

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), the active ingredient in Influvac, is a vaccine presented as a sterile injectable formulation for intramuscular or subcutaneous use. It is intended to induce immunity against the included influenza A and B virus strains, helping to prevent influenza infection in eligible individuals.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Influvac is an influenza vaccine used to prevent infection caused by circulating influenza viruses.

- Seasonal influenza: provides protection against matched influenza A and B strains during the flu season. - Influenza B (Austria strain): induces immunity specifically against the B/Austria/1359417/2021‑like virus. - Influenza A (Victoria strain): induces immunity against the A/Vic strain included in the formulation.

Common and serious adverse reactions may occur following administration of Influvac.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: temperature elevation up to 38 °C. - Headache: transient mild headache. - Myalgia: muscle aches lasting 1–2 days. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - Seizures: infrequent convulsive episodes. - Severe local reaction: extensive swelling or necrosis at injection site. - High‑grade fever: temperature above 39 °C persisting >48 h. - Thrombotic events: very rare clotting complications.

Before administering Influvac, healthcare professionals should observe several safety considerations. - Allergy assessment: avoid vaccination in persons with a known severe allergy to any vaccine component. - Pregnancy counseling: discuss potential benefits and risks with pregnant individuals; vaccination may be considered when indicated. - Immunocompromised patients: evaluate risk‑benefit as response may be reduced. - Acute febrile illness: defer vaccination until the individual has recovered. - Age eligibility: administer only to the age groups approved by regulatory authorities. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Influvac may interact with other medical products; clinicians should review patient medication histories.

Major Interactions (Avoid): - Live vaccines: do not co‑administer with other live attenuated vaccines within four weeks. - Severe allergic reaction to a previous influenza vaccine: avoid repeat dosing.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: may diminish vaccine‑induced immunity, monitor antibody response. - Antipyretic medications: can mask post‑vaccination fever, use judiciously. - Antiviral drugs (e.g., oseltamivir): may interfere with immune response if given concurrently. - Egg allergy: monitor for mild reactions, though most modern vaccines have reduced egg protein.